NCT02868788

Brief Summary

This study will help elucidate the mechanism underlying the cardioprotective and anti-diabetes effect of dietary fiber by exploring a comprehensive set of inflammatory and oxidative stress markers, based on a contemporary understanding of this process. In addition, there have been very few studies that explored the immediate change in oxidative stress and incretin secretion after fiber intake. In this study, the investigators will be able assess the short term metabolic impact of dietary fiber at great details. The result will contribute to dietary recommendation or designing of fiber supplementation for prevention/treatment of diabetes, obesity and cardiovascular disease.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for not_applicable type-2-diabetes

Timeline
Completed

Started Jun 2016

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 14, 2016

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

August 8, 2016

Completed
8 days until next milestone

First Posted

Study publicly available on registry

August 16, 2016

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2018

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2018

Completed
6.3 years until next milestone

Results Posted

Study results publicly available

October 17, 2024

Completed
Last Updated

October 17, 2024

Status Verified

October 1, 2024

Enrollment Period

1.6 years

First QC Date

August 8, 2016

Results QC Date

December 30, 2023

Last Update Submit

October 16, 2024

Conditions

Keywords

inflammationinsulin resistancetype 2 diabetesobesity

Outcome Measures

Primary Outcomes (1)

  • Peak Change in From Baseline in Reactive Oxygen Species (ROS) Generation

    mononuclear cells will be isolated by Ficoll-Hypaque method and ROS will be measured by chemiluminescence as an index of NADPH oxidase activation. Measurment will take place at baseline before the meal intervention and hourly for 5 hrs after the meal. The percent change from baseline at peak effect will be calculated.

    5hr

Secondary Outcomes (3)

  • Peak Change in From Baseline in Nuclear Factor-Kappa B (NFkB) Activation

    5hr

  • Percent Change Toll Like Receptor-4 (TLR-4) Levels

    5hr

  • Change in Plasma Lipopolysaccharides Level From Baseline.

    5hr

Study Arms (2)

high fat high calorie meal (HFHC)

OTHER

Subjects in this arm will receive high fat high calorie (HFHC) meal only

Other: HFHC meal

HFHC plus fiber

EXPERIMENTAL

Subjects in this arm will receive HFHC meal plus dietary fiber supplementation

Dietary Supplement: dietary fiberOther: HFHC meal

Interventions

dietary fiberDIETARY_SUPPLEMENT

Fiber one supplement (32 grams of fiber) will be consumed with 910 Calorie HFHC meal

Also known as: Fiber One
HFHC plus fiber

910 Calorie HFHC meal

HFHC plus fiberhigh fat high calorie meal (HFHC)

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Men and women 18 to 80 years of age
  • Non-smoker (last cigarette at least one month ago)
  • Type 2 diabetes for at least 1 year
  • Body mass index \> 30 kg/m2

You may not qualify if:

  • Participation in any other concurrent clinical trials
  • Pregnancy or premenopausal women who are trying to be pregnant
  • Patients who are incompetent to give consent
  • Patients on non-steroidal anti-inflammatory drugs or steroids
  • Concurrent disease that could disrupt intestinal epithelium and increase permeability to endotoxin, ie Celiac and Crohns disease.
  • Hepatic disease (transaminase \> 3 times normal)
  • Renal impairment (serum creatinine \> 1.5 mg/dl)
  • History of drug or alcohol abuse
  • Use of over the counter or prescribed probiotic supplements.
  • Recent or current antibiotic use.
  • Coronary artery disease (CAD): documented by history of myocardial infarction, angioplasty/stent placement, angina, exercise EKG positive for ischemia or angiographic evidence of CAD

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

ECMC Ambulatory Center, 3rd Floor

Buffalo, New York, 14215, United States

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2InflammationInsulin ResistanceObesity

Interventions

Dietary Fiber

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsHyperinsulinismOverweightOvernutritionNutrition DisordersBody WeightSigns and Symptoms

Intervention Hierarchy (Ancestors)

Dietary CarbohydratesCarbohydratesFoodDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Results Point of Contact

Title
Paresh Dandona
Organization
State University of NY at Buffalo

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
SUNY Distinguished Professor

Study Record Dates

First Submitted

August 8, 2016

First Posted

August 16, 2016

Study Start

June 14, 2016

Primary Completion

January 1, 2018

Study Completion

July 1, 2018

Last Updated

October 17, 2024

Results First Posted

October 17, 2024

Record last verified: 2024-10

Data Sharing

IPD Sharing
Will not share

Locations